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Bioreducible cross-linked core polymer micelles enhance in vitro 
activity of methotrexate in breast cancer cells 
Muhammad Gulfam,a,b Teresa Matini,a Patrícia F. Monteiroa, Raphaël Riva,b Hilary Collins,a Keith 
Spriggs,a Steven M. Howdle,c Christine Jérômeb and Cameron Alexandera* 
Polymer micelles have emerged as promising carriers for controlled release applications, however, several limitations of 
micelle-based drug delivery have also been reported. To address these issues, we have synthesized a functional 
biodegradable and cytocompatible block copolymer based on methoxypoly(ethyleneglycol)-b-poly(ε-caprolactone-co-α-
azido-ε-caprolactone) (mPEG-b-poly(εCL-co-αN3εCL)) as a precursor of reduction sensitive core-crosslinked micelles. The 
synthesized polymer was formulated as micelles using a dialysis method and loaded with the anti-inflammatory and anti-
cancer drug methotrexate (MTX).  The micellar cores were subsequently crosslinked at their pendant azides by a redox-
responsive bis(alkyne). The size distributions and morphology of the polymer micelles were assessed using dynamic light 
scattering (DLS) and transmission electron microscopy, and drug release assays were performed under simplified (serum 
free) physiological and reductive conditions. Cellular uptake studies in human breast cancer cells were performed using 
Oregon-green loaded core-crosslinked micelles. The MTX-loaded core-crosslinked micelles were assessed for their effects 
on metabolic activity in human breast cancer (MCF-7) cells by evaluating the reduction of the dye MTT 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. The apoptosis inducing potential of MTX-loaded core-crosslinked 
micelles was analysed using Hoechst/propidium iodide (PI) and annexin-V/PI assays. The data from these experiments 
indicated that drug release from these cross-linked micelles can be controlled and that the redox-responsive micelles are 
more effective carriers for MTX than non-crosslinked analogues and the free drug in the cell-lines tested. 
 
Introduction  
Block copolymer micelles and vesicles have been extensively 
investigated for site-specific drug delivery and applications 
which require controlled release of active agents.1-4 Although 
delivery of drugs via micellar carriers offers several advantages 
over administration of free drugs, for example prolonged 
circulation time, improved bioavailability, enhanced 
accumulation in disease sites, and fewer side effects,5 some 
limitations of polymer micelles for delivery have also been 
reported.6, 7 These include low stability in vivo, poor 
penetration, modest accumulation in target tissues and 
premature payload discharge in the bloodstream due to 
inadequate control over drug release.8-10 
To overcome such limitations, stimuli-responsive or smart 
polymeric nanocarriers have been developed.11, 12 These 
materials are designed to release payloads in response to 
internal or external stimuli such as light, magnetic fields, 
temperature, enzymes, redox-potential, and reactive oxygen 
species.13, 14 Of particular interest are bioresponsive materials 
which can take advantage of disease-specific stimuli to trigger 
generation of a diagnostic signal or release of a drug.15 
Variations in redox potential and enzyme expression are 
important factors in pathological conditions which might be 
exploited by bioresponsive polymers. For example, it has been 
reported that the reducing potential inside several cancer cells 
(e.g. human breast, prostate, colon and pancreatic cancer 
cells)16 is considerably higher (approximately 100–1000 times) 
than found in the extracellular environment and 
bloodstream.17, 18 Although redox states in cancer cells are 
controlled by complex and variable parameters,19 nevertheless, 
the ranges of redox potential are sufficient that polymers can in 
principle be designed to respond differentially in specific cells 
for tumour selective drug delivery. 
The most-established chemistries for inducing reductive 
responses into polymers are those based on disulfide linkages20. 
These are relatively stable in normal extracellular environments 
but undergo rapid cleavage in the presence of reducing agents 
and reactive thiols, such as glutathione (GSH), when inside 
intracellular components.13, 21 The disulfide links can be 
incorporated in the backbone of a polymer or in a side chain, or 
as a crosslinker inside a nanocarrier by using appropriate 
functional initiators, monomers or chain transfer agents.22-25 
Disulfide units can also be used to conjugate therapeutic agents 
to polymer side chains, allowing for directly triggered drug 
release.26. Various types of disulfide can be used to crosslink 
micelles internally,27 either in the core,9 or at the shell.28 
Although shell crosslinked micelles can offer better stability 
along with higher drug loading, however, a challenge in 
preparation of shell-crosslinked micelles is the need for highly 
dilute conditions to circumvent undesired inter-micellar 
crosslinking, therefore making this route difficult for large-scale 
micellar preparation.29 Moreover, the inter-micellar 
crosslinking in shell cross-linked micelles may also cause the 
agglomeration of nanocarriers into larger particles leading to 
system instability and poor pharmacokinetic properties. 
To overcome these limitations, reduction sensitive core-
crosslinked micelles have been developed. Generally, these 
systems are designed from amphiphilic block copolymers that 
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contain functional moieties (e.g. carboxylic acid, hydrazide, 
lipoyl, dithiopyridine, thiol and alkynyl) in the hydrophobic block 
as pendent or end-capped groups.30 Although many of these 
micelles have demonstrated good stability and ‘stealth’ 
properties,31 the hydrophobic cores have largely been based on 
non-degradable polymers such as polyacrylamide or 
polyacrylate.32, 33 Therefore, analogous micelles composed 
entirely of biologically inert and/or biodegradable polymers 
would be better candidates for clinical use.34    
To address these issues, we have synthesized a functional 
biodegradable and biocompatible block copolymer based on 
methoxypoly(ethyleneglycol)-b-poly(ε-caprolactone-co-α-
azido-ε-caprolactone) (mPEG-b-poly(εCL-co-αN3εCL)) as 
precursor of reduction sensitive core-crosslinked micelles. The 
synthesized block copolymer was characterized by 1H NMR, 13C 
NMR, FT-IR and size exclusion chromatography (SEC). Micelles 
were prepared using a dialysis method and methotrexate as a 
representative drug was loaded into the hydrophobic core of 
the reactive micelles.  
Methotrexate (MTX) was chosen for these studies as it has been 
used against various malignancies including breast cancer, lung 
cancer, head and neck cancer, Hodgkin’s disease, non-
Hodgkin’s lymphoma, osteosarcoma, and childhood acute 
lymphoblastic leukaemia. Although MTX has proven very 
effective in treating certain types of tumours, various dose 
related side effects including acute and chronic hepatotoxicity, 
bone marrow suppression, interstitial pneumonitis, 
nephrotoxicity, and leukopenia, have been reported.35 
Furthermore, poor aqueous solubility (0.01 mg/mL, pKa; 4.7-
5.5), low permeability and the short circulation half-life (2-10 
hours) of the free acid form of MTX are major barriers in 
developing therapeutically successful formulations.36, 37 
In addition, while methotrexate disodium salt exhibits good 
aqueous solubility and can be routinely administered through 
the oral route, plasma MTX concentrations after oral 
administration can vary significantly due to interpatient 
differences in the rate of absorption.38 Moreover, uptake of 
orally administered MTX through the gastrointestinal tract is 
mainly mediated via a saturable transporter, the reduced folate 
carrier (RFC). Accordingly, the bioavailability of orally 
administered MTX cannot increase upon saturation of the RFC 
and higher doses are no more effective.39 
In order to evaluate our carrier system for more predictable and 
effective dosing of MTX, the drug was loaded in the free acid 
form into the core of micelles. Crosslinking at the micellar cores 
was achieved using a bis(alkyne ethyl) disulfide (Scheme 1). The 
size distributions and morphologies of the resultant core-
crosslinked micelles were assessed using dynamic light 
scattering (DLS) and transmission electron microscopy. Drug 
release studies were performed under simulated physiological 
and reductive conditions. Cellular uptake studies in human 
breast cancer (MCF7) cells were performed using Oregon-green 
loaded core-crosslinked micelles. The MTX-loaded core-
crosslinked micelles were assessed for their effects on 
metabolic activity in the MCF7 cells by MTT assays. The 
apoptosis inducing potential of MTX-loaded core-crosslinked 
micelles was analysed using the Hoechst/PI method and was 
further probed by annexin-V/PI assays. The data from these 
assays indicate that drug release from these cross-linked 
micelles can be controlled and that the redox-responsive 
micelles are more effective carriers for MTX than non-
crosslinked analogues and MTX free acid in the cell-lines tested. 
 
Experimental section 
Materials  
All chemicals were used as obtained without additional 
purification unless otherwise stated. 2-chlorocyclohexanone 
(98 %), 3-chloroperoxybenzoic acid (mCPBA 70 %), mono-
methoxy poly(ethylene glycol) (mPEG, Mn-5000 g/mol), ε-
caprolactone (97 %), tin(II) 2-ethylhexanoate (92.5-100 %), 
sodium azide (≥99.5 %), copper (II) sulfate (99.9 %),  ascorbic 
acid sodium salt (≥98 %), pyrene (≥99 %), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDAC, 99 %), 4-(dimethylamino) pyridine (DMAP, ≥99 %), 2-
hydroxyethyl disulfide (90 %), 4-pentynoic acid (95 %), 4-
fluororesorcinol (97 %), 1,2,4-benzenetricarboxylic anhydride 
(97 %), ethylenediaminetetraacetic acid disodium salt dihydrate  
(EDTA, 99 %),  dithiothreitol (DTT, 98 %), and all deuterated 
solvents were purchased form Sigma-Aldrich. Methotrexate (≥ 
98 %), was obtained from VWR International. Cells from a 
human breast cancer cell line (MCF7) were obtained from 
American Type Cell Culture Collection (ATCC). Dulbecco’s 
Modified Eagle Medium (DMEM), fetal bovine serum, L-
glutamine, trypsin-EDTA solution (10 ×), 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, 97.5 %) 
and annexin V-FITC apoptosis detection kit was purchased from 
Sigma-Aldrich. Propidium iodide and Hoechst 33342 stains were 
purchased from Fisher Scientific UK. CellMask Deep Red plasma 
membrane stain was procured from Invitrogen (Thermo Fisher 
Scientific). 
 
Methods 
Synthesis of α-chloro-ε-caprolactone (αClεCL)
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Scheme 1 - Outline illustration for the preparation of MTX-loaded redox-responsive reversibly core-crosslinked micelles, intracellular uptake and mechanism of drug 
release.
The αClεCL monomer was synthesized by oxidation of 2-
chlorocyclohexanone with meta-chloroperoxybenzoic acid 
(mCPBA). 2-Chlorocyclohexanone (5 g, 37.5 mmol) was 
dissolved in 50 mL dichloromethane in a round bottom flask and 
the solution was cooled to 0 °C using an ice bath. Afterwards, 
10 g (40.5 mmol) of mCPBA was carefully introduced into the 
reaction mixture within 10 minutes. The reaction mixture was 
stirred at room temperature for 96 hours, and was 
subsequently cooled to -20 °C. After filtration, the filtrate was 
washed (three times) with 100 mL saturated solutions of 
Na2S2O3, and then with NaHCO3, and once with saturated 
solution of NaCl (100 mL). Finally, the organic phase was washed 
3 times with 100 mL deionized H2O. After drying over 
magnesium sulfate, the organic phase was filtered again, and 
the organic solvent was removed by a rotary evaporator to 
obtain a pale viscous liquid. Finally, the product was purified by 
silica gel column chromatography with solvents of analytical 
purity as mobile phase (hexane: ethyl acetate 9:2, Rf 0.36) to 
obtain αClεCL (3.50 g, 70 % yield). 1H NMR (400 MHz, CDCl3) δ 
(ppm): 4.85-4.81 (COCHCl, t, 1H), 4.69-4.63 (CH2CH2O, m, 1H), 
4.29-4.23 (CH2CH2O, m, 1H), 2.23-1.77 (ClCHCH2CH2CH2, m, 6H).  
 
Synthesis of mPEG-b-poly(εCL-co-αClεCL)  
Briefly, 0.5 g mPEG (0.1 mmol) and 0.104 g αClεCL (0.7 mmol) 
were dissolved in anhydrous toluene and dried by azeotropic 
distillations (3 times) in a glass reactor. Afterwards, 0.4 g εCL 
(3.5 mmol, dried over CaH2 and distilled under reduced pressure 
prior to use) was introduced via a rubber septum using a glass 
syringe and the mixture was heated to 50 °C and stirred for 15 
minutes, until a homogeneous mixture was obtained. SnOct2 
(14 mg, 0.034 mmol, dissolved in CH2Cl2) was finally introduced 
(under nitrogen) and the reaction was stirred at 100 °C for 24 
hours. Finally, the copolymer was dissolved in 5 mL CH2Cl2 and 
was precipitated in anhydrous diethyl ether. The synthesized 
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copolymer was dried in vacuo and characterized by NMR, SEC, 
and FT-IR spectroscopy. Mn = 10100 g/mol (1H NMR). 1H NMR 
(400 MHz, CDCl3) δ (ppm): 4.35 (CH2–O–CO, t, 2H), 4.27 (CO–
CH(Cl)–CH2–CH2–CH2–CH2–O–, t, 7H), 4.21 (CO–CH(Cl)–CH2–
CH2–CH2–CH2–O–, t, 14H), 4.08 (CO–CH2–CH2–CH2–CH2–CH2–
O–H, t, 70H), 3.66 (O–CH2–CH2–O–, m, 586H), 3.40 (CH3–O–, s, 
3H), 2.33 (CO–CH2–CH2–CH2–CH2–CH2–O–H, t, 70H), 2.0 (CO-
CH(Cl)–CH2–CH2–CH2–CH2–O–, m, 28H), 1.76-1.32 (CO–CH2–
CH2– CH2–CH2–CH2–O– and, CO–CH(Cl)–CH2–CH2–CH2–CH2–O–, 
m, 248H). 13C NMR (101 MHz, CDCl3) δ (ppm): 173.52, 70.57, 
64.14, 57.04, 34.11, 28.35, 25.53, 24.57, 22.42. SEC (CHCl3, PS 
calibration): Mn = 13500 g/mol, Ɖ = 1.09. IR: ѵ max/cm-1 735, 
841, 958, 1103, 1148, 1239, 1278, 1341, 1466, 1731, 1954, 
2885. 
 
Synthesis of mPEG-b-poly(εCL-co-αN3εCL)    
The azide bearing amphiphilic block copolymer based on mPEG-
b-poly(εCL-co-αN3εCL) was obtained via the substitution of 
chloro atoms of mPEG-b-poly(εCL-co-αClεCL) by azide groups. 
An amount (500 mg, 0.05 mmol approximately) of mPEG-b-
poly(εCL-co-αClεCL) was dissolved in 5 mL of DMSO. 
Afterwards, sodium azide (34 mg, 150 mol % vs. chloro atoms) 
was introduced and the reaction mixture was stirred at room 
temperature for 24 hours. The reaction mixture was diluted 
with a small amount of CH2Cl2 and copolymer was recovered by 
precipitation in anhydrous diethyl ether. The resulting 
copolymer was dissolved in toluene, and was subsequently 
centrifuged (4000 rpm, 10 min, RT) to remove insoluble salts. 
Finally, the azide bearing copolymer was precipitated in 
anhydrous diethyl ether, filtered and was dried in vacuum and 
characterized by NMR and FT-IR. Mn = 10145 g/mol (1H NMR). 
1H NMR (400 MHz, CDCl3) δ (ppm): 4.35 (CH2–O–CO, t, 2H), 4.23 
(CO–CH(N3)–CH2–CH2–CH2–CH2–O–, t, 14H), 4.08 (CO–CH2–
CH2–CH2–CH2–CH2–O–H, t, 70H), 3.89 (CO–CH(N3)–CH2–CH2–
CH2–CH2–O–, t, 7H), 3.66 (O–CH2–CH2–O–, m, 586H), 3.40 (CH3–
O–, s, 3H), 2.33 (CO–CH2–CH2–CH2–CH2–CH2–O–H, t, 70H), 1.93-
1.34 (CO-CH(N3)–CH2–CH2–CH2–CH2–O–, and, CO–CH2–CH2– 
CH2–CH2–CH2–O–H, m, 266H). 13C NMR (101 MHz, CDCl3) δ 
(ppm): 173.52, 70.57, 64.15, 61.90, 34.13, 28.36, 25.54, 24.58 
22.29. IR: ѵ max/cm-1: 735, 841, 958, 1103, 1148, 1239, 1278, 
1341, 1466, 1731, 1954, 2106, 2885. 
 
Synthesis of mPEG-PCL  
A diblock copolymer based on methoxypoly(ethyleneglycol)-b-
poly(ε-caprolactone) (mPEG-PCL) was synthesised as a control. 
MethoxyPEG (mPEG, 1 g 0.2 mmol) was dissolved in anhydrous 
toluene and dried by azeotropic distillations (3 times) in a glass 
reactor. Afterwards, εCL (1.06 g, 9.2 mmol, dried over CaH2 and 
distilled under reduced pressure prior to use) was introduced 
via a rubber septum using a glass syringe and the mixture was 
heated to 50 °C and stirred for 15 minutes, until a homogeneous 
mixture was obtained. SnOct2 (38 mg, 0.093 mmol, dissolved in 
CH2Cl2) was introduced (under nitrogen) and the reaction was 
stirred at 100 °C for 24 hours. The resultant copolymer was 
dissolved in 5 mL CH2Cl2 and was precipitated in anhydrous 
diethyl ether. The synthesized copolymer was dried in vacuo 
and characterized by 1H NMR and SEC. Mn = 10586 g/mol (1H 
NMR). 1H NMR (400 MHz, CDCl3) δ (ppm): 4.23 (CH2–O–CO, t, 
2H), 4.07 (CO–CH2–CH2–CH2–CH2–CH2–O–H, t, 98H), 3.66 (O–
CH2–CH2–O–, m, 528H), 3.40 (CH3–O–, s, 3H), 2.33 (CO–CH2–
CH2–CH2–CH2–CH2–O–H, t, 100H), 1.70-1.62 (CO–CH2–CH2–
CH2–CH2–CH2–O–H, m, 202H), 1.43-1.37 (CO–CH2–CH2–CH2–
CH2–CH2–O–H, m, 102H). SEC (CHCl3, PS calibration): Mn = 
12803 g/mol, Ɖ = 1.07. 
 
Synthesis of bis-alkyne ethyl disulfide crosslinker   
Anhydrous CH2Cl2 (40 mL) was cooled to 0 °C in a clean dry 
round bottom flask using an ice bath. The solvent was purged 
with nitrogen gas and 1.31 g (8.49 mmol) 2-hydroxyethyl 
disulfide, 3.90 g (20.34 mmol) N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDAC), and 4-pentynoic acid 
(2 g, 20.38 mmol) were introduced into the system. 0.25 g (2.05 
mmol) 4-(dimethylamino)pyridine was dissolved in a small 
amount of dry CH2Cl2 and was subsequently introduced into the 
reaction mixture drop wise under magnetic stirring. The 
reaction contents were stirred for 48 hours at room 
temperature. Afterwards, the organic phase was washed with 3 
x 100 mL of 1M hydrochloric acid solution, 3 x 100 mL of 1M 
sodium hydroxide solution, and 200 mL of 1M NaCl solution. 
The water residues in the organic phase were removed with 
anhydrous MgSO4. After filtration, the solvent was removed 
under reduced pressure to obtain a transparent viscous liquid. 
The final product was purified by silica gel column 
chromatography (hexane: ethyl acetate 4:3, Rf 0.36, 75 % yield), 
and characterized by 1H NMR, and 13C NMR. 1H NMR (400 MHz, 
CDCl3) δ (ppm):   4.39 (t, 4H), 2.95 (t, 4H), 2.63 – 2.57 (m, 4H), 
2.56 – 2.50 (m, 4H), 2.01 (t, 2H). 13C NMR (100 MHz, CDCl3) δ 
(ppm): 171.49, 82.31, 69.18, 62.48, 37.19, 33.22, 14.33.  
   
Preparation of empty and drug/dye loaded un-crosslinked 
micelles 
Empty un-crosslinked micelles of mPEG-b-poly(εCL-co-αN3εCL) 
and mPEG-PCL diblock copolymer were prepared by a dialysis 
method using DMSO as an organic solvent. A sample (50 mg) of 
copolymer was dissolved in 5 mL DMSO and was introduced into 
Milli-Q water (20 mL) under vigorous stirring, using a syringe 
pump with a flow rate of 0.20 mL/min. The solution was stirred 
for 2 hours at room temperature and micelles were purified by 
dialysis overnight against 1 L of Milli-Q water using a cellulose 
dialysis membrane (Spectrapor, cut-off 3500) to remove the 
DMSO. Drug/dye loaded micelles were prepared in a similar 
procedure in which 4 mg methotrexate (MTX) or Oregon-green 
dye and 50 mg copolymer was dissolved in 5 mL DMSO. The 
micellar solution was filtered through a membrane syringe filter 
(pore size: 0.22 μm) (Millex-LG, Millipore Co., USA) before 
further characterisation. 
 
Preparation of empty and drug/dye loaded core-crosslinked 
micelles  
For the preparation of crosslinked micelles, 50 mg (0.005 mmol) 
of mPEG-b-poly(εCL-co-αN3εCL) copolymer and 12 mg (0.038 
mmol) of bis-alkyne-ethyl disulfide crosslinker were 
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Scheme 2 Schematic representation for the synthesis of functional block copolymers and development of redox-responsive micelles. (A) Functional monomer (αClεCL), 
(B) Ring opening polymerization to synthesize mPEG-b-poly(εCL-co-αClεCL) and subsequent nucleophilic substitution reaction to obtain mPEG-b-poly(εCL-co-αN3εCL), 
(C) Synthesis of redox-responsive crosslinker, and (D) Micelles crosslinking via copper-catalyzed azide-alkyne cycloaddition.  
dissolved in DMSO. Afterwards, under vigorous stirring, this 
mixture was introduced dropwise into 20 mL Milli-Q water, 
using a syringe pump with a flow rate of 0.20 mL/min. The 
micellar solution was stirred for 2 hours at room temperature. 
Copper(II) sulfate (0.20 mol equivalent to azide groups) and 
sodium ascorbate (0.20 mol equivalent to azide groups) were 
then introduced into the system. The crosslinking reaction was 
carried out at 36 °C for 24 hours. Finally, EDTA (2 mol equiv. vs. 
Cu) was introduced into the system and the crosslinked micelles 
were dialyzed overnight against 1 L of deionized water. 
Drug/dye loaded core-crosslinked micelles were prepared in a 
similar method in which 4 mg methotrexate (MTX) or Oregon-
green dye and 50 mg copolymer were dissolved in 5 mL DMSO 
in presence of crosslinker. 
 
Determination of drug contents and encapsulation efficiency 
Drug contents and encapsulation efficiencies were determined 
by dissolving a known amount (5 mg) of freeze dried MTX-
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loaded un-crosslinked or MTX-loaded core-crosslinked micelles 
in DMSO. The quantification of methotrexate was performed 
using UV-Vis spectrophotometry (monitoring at λmax = 304 
nm). The amount of loaded drug was calculated using a 
standard curve of MTX in DMSO. Drug content (wt. %) and 
encapsulation efficiency (wt. %) were calculated according to 
the following equations:  
 
Drug content (wt. %)= (weight of MTX in micelles)
(weight of copolymer used)
 × 100 
 
EE % =
(weight of MTX in micelles)
(weight of MTX in feed)
 × 100 
 
Drug release analysis 
The in vitro drug release studies of MTX-loaded un-crosslinked 
and MTX-loaded core-crosslinked micelles were carried out in 
non-reducing (PBS, pH 7.4) and reducing (10 mmol DTT in PBS) 
media. 5 mg of freeze dried MTX-loaded un-crosslinked or core-
crosslinked micelles were re-dispersed in 2mL PBS (pH 7.4) and 
the solution was placed in a dialysis device (Slide-A-Lyzer™ mini 
dialysis device, 3.5K MWCO, Thermo Scientific). The micellar 
solution was dialysed against 45 mL of release media at 37 °C 
and samples (1 mL) were taken at appropriate time points and 
replaced with 1 mL fresh medium. The collected samples were 
freeze dried and dissolved in DMSO. The amount of MTX was 
calculated using UV-Vis spectrophotometry (λmax =304 nm) via 
a standard calibration curve of MTX in DMSO.  
 
Cellular uptake analysis using confocal microscopy 
Human breast cancer cells (MCF7) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10 % fetal bovine 
serum (FBS) and 1 % L-glutamine at 37 °C with 5 % CO2. For 
cellular uptake studies, MCF7 cells (3 x 104 cells/well) were 
seeded on a collagen coated cover glass in a 6-well plate for 24 
hours. Cell culture medium was removed and cells were then 
treated with the fresh medium containing Oregon-green loaded 
un-crosslinked or Oregon-green loaded core-crosslinked 
micelles (100 µg/mL each) and incubated for 3 hours. Cell 
culture medium was removed again and cells were washed with 
PBS (3 times). To label cell membranes, cells were incubated 
with CellMask™ deep red plasma membrane stain (working 
solution concentration 1 µL/mL) for 10 minutes at 37 °C. After 
washing with PBS (3 times), cells were incubated with Hoechst 
dye (working solution concentration 1 µL/mL) for 30 minutes at 
37 °C to label cell nuclei. After removing the labelling solution, 
cells were washed with PBS and were fixed with 4 % 
paraformaldehyde for 15 min at room temperature. After 
fixation, cells were washed with PBS and cover glasses were 
mounted on glass microscope slides using fluorescence 
mounting medium. The uptake of Oregon-green loaded un-
crosslinked or Oregon-green loaded core-crosslinked micelles 
was examined using a Zeiss 510 Meta confocal microscope. 
 
Cellular uptake analysis using flow cytometry 
For cellular uptake studies by flow cytometry, MCF7 cells were 
seeded on a 12-well plate at a density of 7.5 × 104 cells/well in 
1 mL of Dulbecco’s Modified Eagle Medium (DMEM) containing 
10 % fetal bovine serum (FBS) and 1 % L-glutamine for 24 hours 
(37 °C, 5 % CO2). Cell culture medium was removed and was 
replaced with fresh medium containing Oregon-green loaded 
un-crosslinked or Oregon-green loaded core-crosslinked 
micelles (100 µg/mL each) and incubated for 3 hours. Cell 
culture medium was removed again and cells were washed with 
PBS (3 times). Cells were then incubated with 100 µL of 1 × 
trypsin/EDTA solution for 3 minutes (37 °C and 5 % CO2). PBS 
(0.9 mL) was then added into each well and cells were collected 
in labelled FACS tubes and were then centrifuged at 1200 RPM 
for 5 minutes. Supernatant was removed and cells were re-
suspended in 500 µL PBS and analysed using a Beckman Coulter 
FC 500 flow cytometer equipped with 488 and 633 nm co-linear 
lasers. The untreated cells (without micelles) were used as a 
negative control and data were analysed using Kaluza 1.3 
software. 
 
In vitro metabolic activity analysis 
The effects of empty un-crosslinked and core-crosslinked 
micelles, MTX-loaded un-crosslinked and MTX-loaded core-
crosslinked micelles on the metabolic activities of MCF-7 cells 
were analysed using MTT assays. MCF7 cells were seeded on a 
96-well plate at a density of 5 × 103 cells per well in 200 μL of 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10 % 
fetal bovine serum (FBS) and 1 % L-glutamine at 37 °C with 5 % 
CO2 for 24 hours. Cell culture medium was removed and 
replaced with fresh medium containing various concentrations 
of empty un-crosslinked or empty core-crosslinked micelles, 
MTX-loaded un-crosslinked, and MTX-loaded core-crosslinked 
micelles ranging from 100, 250, 500, 750, and 1000 µg/mL. Cells 
were incubated for 48 hours and then 50 µL MTT solution (4 
mg/mL) was added into each well. Cells were incubated for 
another 4 hours and medium containing MTT solution was 
removed and replenished by 150 µL DMSO to dissolve any 
resulting formazan purple crystals.  
The optical densities at 570 nm were measured using a BioTek 
microplate reader (Synergy 2 Multi-Mode Reader) at a 
wavelength of 570 nm. The MTT assay was also repeated with a 
calculated amount of MTX-loaded un-crosslinked or core-
crosslinked micelles equivalent to 4.6, 11.5 23, 36, and 50 
µg/mL of MTX, and also with the same amount of free-MTX as 
a positive control. The percentage of cellular metabolic activity 
was calculated using untreated cells (without micelles) as a 
negative control (100 % metabolic activity). 
 
Apoptosis detection-Hoechst/PI assay 
MCF7 cells were seeded on a 24-well plate at a density of 2 × 
104 cells per well in DMEM containing 10 % FBS and 1 % L-
glutamine at 37 °C with 5 % CO2 for 24 hours. Cell culture 
medium was removed and replaced with fresh medium 
containing a calculated amount of MTX-loaded un-crosslinked 
or core-crosslinked micelles, equivalent to various amounts of 
MTX (4.6, 11.5 23, 36, and 50 µg/mL). Cells were incubated for 
48 hours and cell culture medium was then removed and cells 
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were washed with ice cold PBS. Afterwards, cells were 
incubated with 1 mL Hoechst 33342 solution (10 µL/mL in ice 
cold PBS) at 37 °C for 15 minutes. After removing the labelling 
solution and washing the cells with ice cold PBS, cells were 
incubated with 1 mL propidium iodide (PI) solution (5 µL/mL in 
ice cold PBS) at room temperature for 15 minutes in dark. The 
PI labelling solution was removed and cells were washed (3 
times) with ice cold PBS and were observed immediately under 
an inverted-fluorescence microscope (EVOS™ FL Cell Imaging 
System equipped with a Sony ICX285AQ colour CCD camera). 
The untreated cells (without micelles) were used as a negative 
control and cells treated with various amounts of free MTX (4.6, 
11.5 23, 36, and 50 µg/mL) dissolved in cell culture medium 
were used as positive controls. Cells were also treated with 
various amount of MTX dissolved in DMSO-medium as another 
positive control. A stock solution of MTX was prepared by first 
dissolving MTX in 200 µL DMSO, and volume was made up to 10 
mL with DMEM. This stock solution was further diluted with 
DMEM to obtain the required concentration of MTX. The 
percentages of live, apoptotic, and dead cells were calculated 
using Infinity Analyze software (Infinity Analyze 3R, Lumenera 
Corporation). 
 
Annexin-V/PI apoptosis assay  
MCF7 cells were seeded on a 24-well plate at a density of 7.5 × 
104 cells/well in DMEM containing 10 % FBS and 1 % L-glutamine 
for 24 hours (37 °C, 5 % CO2). Cell culture medium was removed 
and replaced with fresh medium containing a calculated 
amount of MTX-loaded un-crosslinked or MTX-loaded core-
crosslinked micelles, equivalent to various amounts of MTX (4.6, 
11.5, 23, and 50 µg/mL) and cells were then incubated for 48 
hours. After the incubation period, floating cells were collected 
into labelled FACS tubes on ice (4 °C) and attached cells were 
trypsinized and pooled together with corresponding floating 
cells. Samples were centrifuged at 1200 rpm for 5 min at 4 °C 
and supernatants were then discarded and cells were re-
suspended in 5 μL annexin V-FITC along with 100 μL 1 × annexin 
V binding buffer.  Samples were incubated for 15 min at room 
temperature in the dark and were then treated with 10 μL PI (50 
μg/mL in 1 × annexin V binding buffer) along with an extra 400 
μL annexin V binding buffer and were incubated in the dark at 4 
°C for 10 min. Samples were analysed using a Beckman Coulter 
FC-500 flow cytometer and data were analysed using Kaluza 1.3 
software. 
 
Statistical analysis 
All experiments were performed at least three times and data 
are expressed as mean ± standard deviation. The significance of 
the results was evaluated by Student's t-test. The difference 
between two groups was considered statistically significant for 
p < 0.05, and very significant for p < 0.01. 
 
Results 
Synthesis and characterisation of block copolymers  
To obtain a functional amphiphilic block copolymer, we first 
synthesized a functional lactone (i.e. α-chloro-ε-caprolactone) 
from the oxidation of 2-chlorocyclohexanone by 3-
chloroperoxybenzoic acid (mCPBA) as shown in Scheme 2A. The 
crystals of unreacted mCPBA and its reduced form (m-chloro 
benzoic acid) were removed by filtration, whereas, the 
remaining residues of both acids in the product mixture were 
quenched and removed by extraction with saturated solutions 
of sodium thiosulfate and sodium bicarbonate. The oxidation of 
2-chlorocyclohexanone resulted in two isomers i.e. αClεCL, and 
εClεCL, in a 95/5 molar ratio. In this work, the αClεCL was 
purified by silica gel column chromatography with high yield (70 
%) and high purity, as also revealed by 1H NMR spectroscopy 
(Fig. 1A). The appearance of chemical shifts at 4.69 and 4.29 
ppm in 1H NMR spectrum, confirmed the formation of the 
functional lactone. 
The functional copolymer based on mPEG-b-poly(εCL-co-
αClεCL) was obtained by the ring-opening polymerization of 
αClεCL and εCL. The PEG bearing one OH functional group at the 
ω-chain end was used as an initiator, whereas tin octoate was 
used as a catalyst as shown in Scheme 2B. The polymerization 
was performed in bulk (without solvent) at 100 °C. The 
disappearance of monomer signals in 1H NMR spectrum 
revealed quantitative conversion of both monomers after 24 
hours. The block copolymer was purified by precipitation in 
diethyl ether from a solution in CH2Cl2 to remove catalyst 
residues. The 1H NMR spectrum of mPEG-b-poly(εCL-co-αClεCL) 
is shown in Fig. 1B. The molar mass of mPEG-b-poly(εCL-co-
αClεCL) copolymer was calculated by the comparison of the 
relative intensity of the proton of PCL at 2.33 ppm (CH2-C(O), 
peak “k", in Fig. 1B) and relative intensity of the proton of 
poly(αClεCL) at 4.21 ppm (CO–CH(Cl)–CH2–CH2–CH2–CH2–O–, 
peak “j”, in Fig. 1B) with the methoxy end group of the mPEG 
(3.3 ppm, peak “a” in Fig. 1B). Integration of the 1H NMR 
spectrum revealed that the molar mass of synthesized block 
copolymer was 10100 g/mol with a degree of polymerization 
(Dp) of 7 for αClεCL and 35 for εCL. The NMR-derived molar 
mass was in good agreement with the theoretically achievable 
molar mass based on the co-monomers feed. 
The number average molecular weight (Mn) and dispersity (Ð) 
were determined using size exclusion chromatography (SEC). 
The shift towards lower elution time of mPEG-b-poly(εCL-co-
αClεCL) (Fig. S3) as compared to the mPEG was an evidence of 
increase in molar mass after polymerization. The SEC analysis of 
mPEG-b-poly(εCL-co-αClεCL) block copolymer showed number 
average molar mass of 13500 g/mol with dispersity of 1.09.  
In a second step, the pendent chloro atoms of copolymer were 
converted into azides in order to synthesize a ‘clickable’ block 
copolymer. The 1H NMR (Fig. 1C) and 13C NMR (Fig. S2) spectra 
of mPEG-b-poly(εCL-co-αN3εCL) revealed the complete 
conversion to azides, as also confirmed by FT-IR (Fig. 1D). 
Specifically, the IR spectrum of mPEG-b-poly(εCL-co-αN3εCL) 
showed the expected absorption of the azide group at 2106 cm-
1. 
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Fig. 1 Characterization of the functional monomer and block copolymers. (A) 1H NMR spectrum of αClεCL, (B) 1H NMR spectrum of mPEG-b-poly(εCL-co-αClεCL), (C) 1H 
NMR spectrum of mPEG-b-poly(εCL-co-αN3εCL), and (D) FTIR spectra of block copolymers before and after azide substitution.
Preparation and characterization of MTX-loaded redox-responsive 
core-crosslinked micelles 
To incorporate reduction sensitive bridges into the core of the 
micelles, a bis-alkyne-ethyl disulfide crosslinker was synthesized 
by reacting 4-pentynoic acid with bis(2-hydroxyethyl) disulfide, 
using EDAC as a carboxylic acid activating agent and DMAP as a 
catalyst (Scheme 2C). The resulting compound was purified by 
silica gel column chromatography (75 % yield). The structure of 
bis-alkyne-ethyl disulfide crosslinker was confirmed by 1H NMR 
and 13C NMR (Fig. 2A, and Fig. S5, respectively). The 1H NMR 
signals at 4.39 ppm and 13C NMR signals at 62.48 ppm confirmed 
the formation of the crosslinker.  
Reactive micelles based on mPEG-b-poly(εCL-co-αN3εCL) were 
then prepared using a dialysis method in which DMSO was used 
as an organic solvent. Methotrexate was loaded into the 
hydrophobic cores of the micelles which were subsequently 
crosslinked by the bis-alkyne ethyl disulfide crosslinker using 
copper catalyzed azide-alkyne cycloaddition as shown in 
Scheme 2D. The kinetics of the ‘click’ reaction were monitored 
by FT-IR (Fig. 2B). The infrared absorption peak at 2106 cm-1 
(characteristic of the azide group) completely disappeared in 
favour of a new peak at 1660 cm-1 (typical of the triazole ring), 
as also reported previously,40 suggesting essentially complete 
cross-linking. 
The size distributions and morphologies of micelles were 
analysed using DLS and TEM, respectively. The characterization 
data of micelles are summarized in Table 1. The empty micelles 
were of an average size of 36 ± 7 nm as shown by DLS (Fig. 3A, 
right image) with spherical morphologies as confirmed by TEM 
(Fig. 3A, left image). These sizes were very similar to those of 
unsubstituted mPEG-PCL micelles (34 nm, Fig S6). By contrast, 
the average size of MTX-loaded un-crosslinked micelles was 53 
± 9 nm with a summated poly dispersity index (0.12 ± 0.05) as 
revealed by DLS (Fig. 3B right image). TEM analysis (Fig. 3B left 
image) showed the predominantly spherical morphology of 
MTX-loaded micelles with average sizes of 46 nm (Fig. 3B middle 
image). MTX-loaded core-crosslinked micelles were slightly 
larger (67 ± 12 nm, and 63 nm) as determined by DLS (Fig. 3C 
right image) and TEM (Fig. 3C left image), respectively, as 
compared with MTX-loaded un- crosslinked micelles. 
The zeta potentials of the empty, MTX-loaded un-crosslinked 
and MTX-loaded core-crosslinked micelles were near to neutral 
(-2.81 ± 0.91, -3.50 ± 1.25, and -2.30 ± 2.21 mv, respectively) as 
shown in Fig. S8. 
Drug contents and encapsulation efficiency of MTX-loaded un-
crosslinked and core-crosslinked micelles were determined
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Fig. 2 Characterization of redox-responsive crosslinker and core-crosslinked micelles. (A) 1H NMR spectrum of crosslinker and (B) FTIR spectra of freeze-dried MTX-
loaded un-crosslinked and core-crosslinked micelles. 
using UV-Vis spectrophotometry (λmax = 304 nm) through a 
standard curve of MTX in DMSO.  The core-crosslinked micelles 
showed significantly higher drug contents (4.9 ± 0.6 wt. %) and 
better encapsulation efficiency (61.8 ± 7.4 %) as compared with 
un-crosslinked micelles (3.1 ± 0.4 wt. %, and 39.3 ± 5.2 %, 
respectively), as shown in table 1.  
To study the cellular uptake of micelles, Oregon-green loaded 
un-crosslinked micelles and Oregon-green loaded core-
crosslinked micelles were prepared. For this purpose, Oregon-
green dye was synthesized by the methanesulfonic acid 
catalysed reaction of 4-fluroresorcinol with trimellitic anhydride 
(Scheme. S1). The structure of Oregon-green was confirmed by 
1H NMR (Fig. S9) and electrospray ionization mass spectrometry 
(Fig. S10). The Oregon-green loaded un-crosslinked micelles and 
Oregon-green loaded core-crosslinked micelles were of mean 
sizes of 43 and 52 nm, respectively, as revealed by DLS 
measurements (Fig. S11). 
 
In vitro drug release studies 
Drug release of MTX from the micelles was carried out under 
reducing and non-reducing conditions at 37 °C. Due to the 
complexities of the intracellular environment, in which many 
reducing species may be present at different times, GSH alone 
was not used in these model studies,19 and instead DTT was 
used as a simple known reductant. The amount of drug release 
was determined using UV-Vis spectrophotometry monitoring at 
304 nm. As shown in Fig. 4, in PBS (pH 7.4), MTX-loaded un-
crosslinked micelles showed a burst release of drug during the 
first 12 hours (35 % drug release) followed by a steady and 
temporal drug release during which 90 % drug was released up 
to 96 hours. In contrast, core-crosslinked micelles exhibited a 
reduced burst release of MTX in non-reducing conditions, with 
~ 20 % MTX detected in the dialysate during the first 12 hours. 
Methotrexate was mostly retained by core-crosslinked micelles 
in PBS at 37 °C even up to 96 h, after which time 76 % MTX was 
still retained in the micelles. However, MTX-loaded core-
crosslinked micelles exhibited about 60 % drug release at 12 
hours and 89 % drug release at 24 hours under reducing 
conditions (10 mmol DTT). 
 
In vitro cellular uptake 
In vitro cellular uptake of un-crosslinked and reversibly core-
crosslinked micelles was investigated using flow cytometry and 
confocal laser scanning microscopy. For this purpose, Oregon- 
green loaded un-crosslinked and core-crosslinked micelles were 
incubated for 3 hours with human breast cancer (MCF7) 
Table 1. Characterization data of empty, drug loaded un-crosslinked, and drug loaded core-crosslinked micelles. (SD ~ standard deviation, NA~ not applicable, PDI ~ 
poly dispersity index. 
Micelles type Size (d. nm) ± SD PDI ± SD Zeta potential 
(mv) ± SD 
Drug content 
(Wt. %) ± SD 
Encapsulation 
efficiency (%) ± SD 
Empty micelles 36 ± 7 0.21 ± 0.02 -2.81 ± 0.91 NA NA 
MTX-loaded 
un-crosslinked micelles 
53 ± 9 0.12 ± 0.05 -3.50 ± 1.25 3.14 ± 0.42 39.3 ± 5.2 
MTX-loaded core-
crosslinked micelles 
67 ± 12 0.24 ± 0.03 -2.30 ± 2.21 4.94 ± 0.60 61.8 ± 7.5 
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Fig. 3 Size and morphological characterization of micelles. (A) Empty micelles, (B) MTX-loaded un-crosslinked micelles, and (C) MTX-loaded core-crosslinked micelles. 
Left images showing TEM micrographs, middle images showing size distributions calculated using ImageJ software, and right images represent size distribution 
measured using dynamic light scattering. 
cells. Flow cytometry analysis showed that Oregon-green 
loaded un- crosslinked and core-crosslinked micelles were 
efficiently endocytosed by MCF7 cells (Fig. 5A and 5B, 
respectively). Cells incubated without micelles were used as a 
negative control to correct the auto fluorescence. The median 
fluorescence intensities arising from negative control, Oregon-
green loaded un-crosslinked and Oregon-green loaded core-
crosslinked micelles were 5.23, 62.08, and 63.35 (arbitrary 
units), respectively. Flow cytometry analysis revealed that the 
extents of uptake of un-crosslinked and core-crosslinked 
micelles were 93 and 94 %, respectively, showing that 
crosslinking the micelle-core did not negatively affect cellular 
entry of micelles.   
Confocal laser scanning microscopy was used to analyse the 
intracellular localization of micelles. MCF7 cells were incubated 
with Oregon-green loaded un-crosslinked and core-crosslinked 
micelles for 3 hours. Cell membranes were stained with 
CellMask™ deep red plasma membrane stain, whereas cell 
nuclei were stained with Hoechst dye. Fig. 5C shows the CLSM 
images of cellular uptake of Oregon-green loaded un-
crosslinked micelles. It is apparent that Oregon-green loaded 
micelles were internalized by MCF7 cells and were localized 
mostly in the cytoplasm at the 3-hour time-point.  
Interestingly, Oregon-green loaded core-crosslinked micelles 
were localized both in the cytoplasm and in the nuclei of the 
MCF7 cells as shown by the green fluorescence in merged CLMS 
images (Fig. 5D). The observed green fluorescence located in 
the proximity of cell nuclei was probably due to the localization 
of core-crosslinked micelles or delivery of dye following 
endosomal/lysosomal escape.41 
 
MTT assay/cytotoxicity studies 
The in vitro effects of the empty mPEG-b-poly(εCL-co-αN3εCL) 
micelles and their crosslinked counter parts were investigated 
in MCF7 cells using MTT assays. For this purpose, MCF7 cells 
were treated with various amounts of empty un-crosslinked and 
crosslinked micelles for 48 hours. The results of MTT assays are 
depicted in Fig. 6A. The MTT assay results showed more than 90 
% metabolic activity of MCF7 cells treated with  
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Fig. 4 Analysis of methotrexate (MTX) release from MTX-loaded un-crosslinked 
and core-crosslinked micelles at 37 °C. 
un-crosslinked and core-crosslinked empty micelles up to 
concentrations of 500 µg/mL as compared with the negative 
control. At maximum tested concentration of 1000 µg/mL, cells 
treated with un-crosslinked and core-crosslinked micelles 
showed metabolic activities of 90.8 ± 2.7, and 75 ± 2 %, 
respectively.   
In contrast, MTX-loaded un-crosslinked and MTX-loaded core-
crosslinked micelles decreased the metabolic activity of MCF7 
cells in a dose dependent pattern (Fig. 6A). Specifically, MTX-
loaded un-crosslinked micelles showed a metabolic activity of 
50.8 ± 4 and 45.4 ± 2.5 % at concentrations of 500 and 1000 
µg/mL, respectively. Interestingly, MTX-loaded core-crosslinked 
micelles proved to be significantly more potent as compared to 
un-crosslinked counterparts. At concentrations of 500 and 1000 
µg/mL, MTX-loaded core-crosslinked micelles decreased the 
metabolic activity of MCF7 cells to 14 ± 10.5, and 8.2 ± 3.6 %, 
respectively.  
Since the drug contents of MTX-loaded un-crosslinked and core-
crosslinked micelles were different, therefore, MTT assays were 
also repeated with calculated amounts of MTX-loaded un-
crosslinked or core-crosslinked micelles, equivalent to various 
amounts of free MTX (4.6, 11.5, 23, 36 and 50 µg/mL). The 
metabolic activities of MCF7 cells as a function of MTX 
concentrations are shown in Fig. 6B. It was observed that the 
metabolic activities of MCF7 cells treated with MTX-loaded 
core-crosslinked micelles, equivalent to 50 µg/mL of MTX, were 
significantly decreased as compared to the MTX-loaded un-
crosslinked micelles and free MTX. These findings indicated that 
crosslinked micelles enhanced the cytotoxicity of MTX to a 
greater extent as compared with the free MTX and MTX-loaded 
un-crosslinked micelles. 
 
Apoptosis inducing potential of MTX-loaded core-crosslinked 
micelles 
In order to investigate whether the cell death observed in MCF7 
cells treated with free MTX and MTX-loaded formulations could 
be due to apoptosis, Hoechst/PI double staining was 
performed. The morphological changes in cell nuclei were 
analysed using a fluorescence microscope. The MCF7 cells 
incubated with different concentrations of free MTX and MTX-
loaded formulations showed obvious morphological changes in 
cell nuclei after treatment for 48 hours, as compared with the 
control untreated cells. As shown in Fig. S-12, the untreated 
cells were regular and intact with less bright blue nuclei and 
without red fluorescence. In contrast, cells treated with MTX-
loaded un-crosslinked and core-crosslinked micelles (Fig. 7A 
and 7B, respectively) and free MTX (Fig. S13A) showed 
characteristic features of apoptosis and cell death.  
The percentage of apoptotic and dead cells increased 
correspondingly in a dose dependent manner after treatment 
with MTX-loaded formulations. Specifically, MTX-loaded un-
crosslinked micelles at 50 µg/mL equivalent of MTX resulted in 
20 ± 1.8 and 15 ± 2.3 % apoptotic and dead cells, respectively, 
as shown in Fig. 7C. The percentage of apoptotic and dead cells 
also increased after treatment with MTX-loaded core-
crosslinked micelles (Fig. 7D) as compared with their un-
crosslinked counterparts. In particular, MTX-loaded core-
crosslinked micelles at 23 µg/mL equivalent of MTX resulted in 
approximately 46 ± 6 and 33 ± 5 % apoptotic and dead cells, 
respectively. When the amount of MTX-loaded core-crosslinked 
micelles was increased to 50 µg/mL equivalent of MTX, the 
percentage of dead cells was also increased showing 78 ± 8 % 
dead cells and 9 ± 4 % apoptotic cells. However, MCF7 cells 
treated with free MTX (Fig. S13B) showed a lower percentage of 
apoptotic and dead cells as compared with MTX-loaded 
formulations. At 50 µg/mL free MTX concentration, the 
percentages of apoptotic and dead cells were 10 ± 3 and 8 ± 2 
%, respectively.  
To further confirm that cell death was induced via apoptosis by 
MTX-loaded formulations, annexin V-FITC/PI assays were 
performed. The proportion of live, apoptotic, and dead cells 
stained with annexin V-FITC/PI assay were calculated using flow 
cytometry. The forward scattering (FS) and side scattering (SS) 
were integrated to provide information about cell size, and cell 
morphology, respectively. The proportion of live, apoptotic, and 
dead cells were calculated by the comparison of fluorescence 
corresponding to annexin V-FITC (FL1) and fluorescence 
corresponding to propidium iodide (FL3). The results of annexin 
V-FITC/PI assays are shown in Fig. 8. The negative control cells 
(without treatment) appeared to be regular and with low 
fluorescence (i.e. auto fluorescence) as shown in Fig. S14A. The 
auto fluorescence generated by control cells was subtracted 
from the flow cytometry data of treated samples by applying 
appropriate gating.  
The flow cytometry results revealed that MCF7 cells treated 
with MTX-loaded un-crosslinked micelles exhibited dose 
dependent increases in the proportions of apoptotic and dead 
cells (Fig. 8C) as compared to untreated cells (Fig. S14C). The 
MTX-loaded un-crosslinked micelles at 50 µg/mL equivalent to 
free MTX gave rise to 23 ± 4 and 8 ± 5 % apoptotic and dead 
cells, respectively. In contrast with the un-crosslinked micelles, 
the MTX-loaded core-crosslinked micelles enhanced the 
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Fig. 5 Cellular uptake studies of micelles. (A) Fluorescence assisted cell sorting analysis of cellular uptake in MCF7 cells incubated with Oregon-green loaded un-
crosslinked micelles, and (B) Oregon-green loaded core-crosslinked micelles. Cells incubated without micelles were used as a negative control to correct auto 
fluorescence and to apply appropriate gating. (C) Confocal laser scanning microscopic images of cellular uptake in MCF7 cells cultured with Oregon-green loaded un-
crosslinked micelles, and (D) Oregon-green loaded core-crosslinked micelles. Nuclei of cells were stained with Hoechst (blue fluorescence) and cell membranes were 
stained with CellMask™ deep red plasma membrane stain (red fluorescence). 
proportion of apoptotic and dead cells even at moderate 
concentrations of 23 µg/mL equivalent of MTX, showing 50 ± 9 
and 39 ± 11 % apoptotic and dead cells, respectively (Fig 8D). 
Higher concentrations of MTX-loaded core-crosslinked micelles 
(50 µg/mL equivalent of MTX) were very effective against MCF7 
cells (82 ± 12 % dead cells). Assays in which cells were treated 
with free MTX control (50 µg/mL) resulted in fewer apoptotic 
(approximately 15 ± 4 %) and dead cells (4 ± 3 %), as shown in 
Fig. S14B and S14C. The findings obtained from annexin V-
FITC/PI assay were thus in agreement with Hoechst/PI double 
staining and MTT assays. 
To investigate the probability that low in vitro cytotoxicity of 
free MTX could be due to its poor aqueous solubility and 
reduced permeability, assays with MTX-DMSO controls were 
performed. The various concentrations of MTX dissolved in 
DMSO-medium were incubated with MCF7 cells for 48 hours. 
The results are shown in Fig. S15. Interestingly, there was no 
significant difference found in the apoptotic activity
  Paper 
  
 
Fig. 6 Cytotoxicity analysis of micelles cultured with MCF7 cells for 48 hours. (A) Cytotoxicity of Empty and MTX-loaded un-crosslinked and core-crosslinked micelles, 
and (B) Metabolic activity of MCF7 cells as a function of MTX concentration. Error bars showing standard deviation (n=3). MTT assays were used to analyse the metabolic 
activity of MCF7 cells. * = significant (p < 0.05) and **= very significant (p < 0.01).  
as compared with free MTX (without DMSO) as a positive 
control. 
 
Discussion 
In this study, a synthesized α-chloro-ε-caprolactone monomer 
was used as a precursor to generate functional amphiphilic 
block copolymer of mPEG-b-poly(εCL-co-αClεCL) via ring 
opening polymerization. This amphiphilic block copolymer, with 
a narrow molecular weight distribution, was then substituted at 
the pendant chloro-alkyl positions with azides to obtain a 
‘clickable’ block copolymer. Methotrexate (MTX)-loaded redox-
responsive reversible core-crosslinked micelles were then 
derived from this mPEG-b-poly(εCL-co-αN3εCL) block 
copolymer and formulated using a dialysis method.  
In order to concentrate the bis-alkyne ethyl disulfide crosslinker 
in the hydrophobic part of the micelles, the crosslinker was 
directly added in the organic phase during micelles formation 
along with the copolymer and MTX. Upon drop-wise addition of 
this mixture into water, it was intended that the bis-alkyne ethyl 
disulfide crosslinker and MTX would be retained in the 
hydrophobic region of the micelles. However, the crosslinker 
still be accessible to Cu(I) ions when the click reaction 
proceeded between the pendant azide groups of the copolymer 
backbone and the alkyne groups of the crosslinker as the DMSO 
and aqueous phases mixed. 
The MTX-loaded core-crosslinked micelles were larger than 
their un-crosslinked counterparts as shown in Fig. 3. The larger 
sizes of the core-crosslinked micelles were likely due to the 
accumulation of crosslinker in the hydrophobic core of micelles. 
Moreover, conformational rearrangements driven by triazole 
ring formation, which in turn caused decreased free movement 
of the chains of the copolymer, could also contribute to larger 
cores of the micelles, as has been reported previously.27 
The hydrodynamic diameters of micelles in all the formulations 
as measured by DLS were larger than those of the air-dried 
micelles measured with TEM, as expected based on the 
hydration of the polyethylene glycol shell of the copolymeric 
micelles in solution. The zeta potential measurements showed 
near to neutral surface charges of the micelles (Fig. S8), again 
attributable to the neutral hydrophilic PEG shell that extended 
out into the aqueous phase and inhibited the aggregation of 
micelles through steric stabilization. 
The drug loading studies of core-crosslinked micelles revealed 
that the crosslinking step increased the drug contents 
compared to the un-crosslinked micelles. The better 
encapsulation efficiency of crosslinked micelles could be 
attributed to a more tightly packed core with interconnected 
networks of crosslinked bridges providing more effective 
diffusion barriers to egress of MTX from the formulation. 
Various factors have been reported to influence drug loading of 
polymeric micelles including polymer-drug compatibility,42 size 
of the micelle core,43 presence and extent of micellar 
crosslinking, presence of specific functional groups in the 
copolymer,44 and molecular weight and chemical structure of 
the encapsulated agents.   
From the in vitro release experiments (Fig. 4), it was apparent 
that un-crosslinked micelles showed greater burst release of 
MTX compared to core-crosslinked micelles. The latter retained 
most of the drug payload in the absence of exogenous reducing 
agent, however, rapid release of MTX was observed in reducing 
environments for the disulfide 
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Fig. 6 Fluorescence microscopic analysis of apoptotic and dead cells in MCF7 breast cancer cells treated for 48 hours with (A) MTX-loaded un-crosslinked micelles and 
(B) MTX-loaded core-crosslinked micelles. a, b, c, d, and e, represent the MTX-loaded formulations equivalent to various amounts of free MTX (4.6, 11.5, 23, 36 and 50 
µg/mL, respectively). Hoechst 33342 dye was used to detect live and apoptotic cells, whereas propidium iodide (PI) was used to detect dead cells. Scale bars ~ 40 µm. 
(C-D) Quantification of live, apoptotic, and dead cells in MCF7 cells treated with MTX-loaded un-crosslinked micelles and MTX-loaded core-crosslinked micelles, 
respectively. The percentage of live, apoptotic and dead cells was calculated by Infinity Analyze software. Error bars represent standard deviation (n=3). *= significant 
(p < 0.05) and **= very significant (p < 0.01). 
crosslinked polymer micelles. Various factors are known to 
affect the drug release from polymeric micelles such as polymer 
degradation, wettability, molecular weights of hydrophilic and 
hydrophobic blocks, glass transition temperature, binding 
affinity between the drug and copolymer.45 The incorporated 
drug may accumulate at various places inside the micelle e.g. at 
the interface between the core and shell of the micelle, within 
the micelle-core and to a lesser extent within the corona or shell 
of the micelle. Therefore, the localization of the drug within the 
micelle can also play an important role in the release kinetics of 
the encapsulated drug. 
In this study, MTX release rate was not expected to be 
influenced by polymer degradation owing to the known slow 
hydrolysis rate of PCL. While the polymers were designed to be 
ultimately biodegradable, as PCL itself is broken down by 
esterolytic cleavage,46, 47 we also intended for the polymer main 
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chains to be stable enough over the time period of cell culture 
experiments such that any drug release resulting from disulfide 
cleavage would be immediately detectable above any drug 
liberated by ‘background degradation’ of PCL components. 
Prior reports have shown that PEG-PCL co-polymer micelles 
similar to those prepared in this study decreased in molar mass 
by ~ 6% over a 12 week period in PBS.48 Thus we were confident 
that backbone degradation would be much slower than cross-
link cleavage due to disulfide reduction. Therefore, the initial 
‘burst release’ from un-crosslinked micelles was likely to have 
been due to the rapid contact of the aqueous medium with a 
fraction of MTX localized on the corona or at the interface 
between the corona and micelle-core. 
Fig. 7 Annexin V-FITC/PI assays to measure the apoptotic and dead cells in MCF7 breast cancer cells cultured with (A) MTX-loaded un-crosslinked micelles, (B) MTX-
loaded core-crosslinked micelles. a, b, c, and d represent the MTX concentration in micelles (4.6, 11.5, 23, and 50 µg/mL, respectively). J1 ~ necrotic cells, J2 ~ dead 
cells, J3 ~ live cells, and J4 ~ apoptotic cells.  (C-D) Flow cytometric quantification of live, apoptotic, and total dead cells from MCF7 cells treated with MTX-loaded un-
crosslinked micelles and MTX-loaded core-crosslinked micelles, respectively. *= significant (p < 0.05) and **= very significant (p < 0.01). 
The steady or temporal drug release phase was probably due to 
the drug diffusion from the micelle-core into the release 
medium, as previously described.49 In contrast, MTX-loaded 
core-crosslinked micelles released lower amounts of drug under 
non-reducing conditions showing that core-crosslinked micelles 
more efficiently contained the drug payload compared to the 
un-crosslinked systems. 
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The fast MTX release from core-crosslinked micelles under a 
reducing environment was likely due to the cleavage of disulfide 
bridges resulting in de-crosslinking and ‘opening’ of the micellar 
cores. Overall, redox-responsive reversibly core-crosslinked 
micelles efficiently restricted MTX release in non-reducing 
buffer conditions, however, introduction of DTT into the 
micellar suspensions caused cleavage of the internal micelle 
crosslinks, which subsequently facilitated drug release. 
Analysis of the cellular uptake of the micelles was performed 
using Oregon-green as a fluorescent probe. Oregon-green 
loaded un-crosslinked and core-crosslinked micelles were 
efficiently taken up by MCF7 cells and there was no significant 
difference found in the magnitude of the cellular uptake of both 
type of micelles, as observed by flow cytometry (Fig. 5A and 5B, 
respectively) and confocal microscopy studies (Fig. 5C and Fig. 
5D, respectively). However, confocal microscopy revealed that 
un-crosslinked micelles were mostly localized in cytoplasmic 
regions of the MCF7 cells, whereas, core-crosslinked micelles 
were accumulated both in the cytoplasmic and in perinuclear 
regions of MCF7 cells.   
It has been reported that nanocarriers can penetrate into 
certain solid tumours due to the leaky vascular system existing 
in these types of cancer tissues. This phenomenon is known as 
the enhanced permeability and retention (EPR) effect,50 and has 
been shown to allow materials above a hydrodynamic volume 
threshold to partition selectively from the circulation into 
tumour tissue.  If, after penetrating the target site, the retained 
nanocarriers can release a drug payload in the vicinity of cancer 
cells, an effective localisation of drug can be obtained, which is 
better in terms of the therapeutic window for the drug. In 
addition, many tumours lack effective lymphatic drainage, 
hence increasing the retention of nanoscale drug delivery 
systems in the target site.51 This retention of nanocarriers 
contributes to the further accumulation of the drug at the 
tumour locality. Polymeric micelles are considered to be good 
candidates to take advantage of the EPR effect due to the 
possibility that micelle-size can easily be tuned by controlling 
the molecular weights of hydrophilic and hydrophobic blocks 
and other parameters.  
In any clinical application, drug-loaded nanocarriers must pass 
through various transport barriers to reach their targets. 
Specifically, translocation of injected drug delivery systems 
across the plasma membrane barrier is a prerequisite. Plasma 
membranes play an important role in control of cellular 
communication and cell division regulated by endocytosis. It 
can be assumed that cellular uptake of Oregon-green loaded 
un-crosslinked and core-crosslinked micelles was through 
passive caveolin-mediated endocytosis, as no targeting ligands 
were grafted to the micelles.  
Thus, after being internalized, the micelles were likely to have 
been entrapped into endocytic vesicles, and trafficked into 
endo/lysosomal compartments. The endosomes and lysosomes 
are acidified vesicles containing multiple enzymes that can 
degrade certain foreign material.52, 53 In this study, the 
localization of Oregon-green loaded un-crosslinked micelles 
mostly in the non-nuclear regions of the MCF7 cells was likely 
to be attributable to the dis-assembly of micelles, and 
ultimately release of Oregon-green in the endosomes or 
lysosomes. This might have restricted the un-crosslinked 
micelles or Oregon-green to the cytoplasmic regions of the 
MCF7 cells. In control experiments in which MCF7 cells were 
treated with free Oregon-green, we found that the 
unencapsulated dye mostly accumulated in the plasma 
membranes or cytoplasmic regions of MCF7 cells (Fig. S16). This 
was most likely due to the relatively low aqueous solubility and 
cell membrane affinity of Oregon-green.54 In contrast, both 
micelle types internalised more efficiently than the free dye, but 
the crosslinked micelles may have been able to survive 
lysosomal degradation to a greater extent due to better 
colloidal stability and more robust cores. This might in turn have 
enabled more rapid transport out of lysosomal compartments, 
passage into the cytosol and transport or facilitated delivery of 
Oregon-green to the nuclei of MCF7 cells.41 The transport of 
nanocarriers into the cell nucleus is a complex phenomenon 
involving nuclear pore complexes and passive diffusion or 
receptor-regulated nuclear transport mechanisms.55 
Experiments to probe these mechanisms with the cross-linked 
micelles are currently in progress.  
The metabolic activity investigations using MTT assays showed 
that empty un-crosslinked and core-crosslinked micelles were 
essentially non-toxic to MCF7 cells. In contrast, MTX-loaded 
formulations significantly enhanced the cytotoxicity of MTX 
(Fig. 6A-B). Specifically, MTX-loaded core-crosslinked micelles 
were found to be more toxic to breast cancer cells as shown by 
the declined cell viability of 8.2 % at 50 µg/mL equivalent to 
MTX, as compared with same concentrations of free-MTX (74 % 
cell viability) and MTX-loaded un-crosslinked micelles (45 % cell 
viability).  
In order to confirm whether the cell death in tumour cells 
treated with MTX-loaded formulations was due to the onset of 
apoptosis, confirmatory tests were implemented. Typically, the 
initiation of apoptosis in cells results in condensation or 
fragmentation of chromatin due to the condensed nuclei of 
apoptotic cells, which can be detected by fluorescence 
microscopy using a cell permeable nucleic acid labelling blue 
fluorescent dye, Hoechst 33342. Concurrently, dead cells can be 
detected by staining with propidium iodide (a dye which 
exhibits strong fluorescence on DNA-binding). Propidium iodide 
cannot cross the membranes of live cells, however, dead or 
necrotic cells can be stained with PI due to their compromised 
cell membrane integrity. The MCF7 cells treated with MTX-
loaded un-crosslinked and core-crosslinked micelles, free MTX, 
and MTX-DMSO control showed characteristics features of 
apoptosis such as chromatin condensation and fragmentation, 
cell shrinkage, and formation of apoptotic bodies as shown in 
Fig. S17. Specifically, apoptotic nuclei clearly exhibited bright 
blue fluorescence with condensed or fragmented chromatin. 
The dead cells or the cells with late apoptosis stage showed pink 
fluorescence. The findings of the Hoechst/PI assays were 
consistent with the MTT assays, showing that MTX-loaded core-
crosslinked micelles induced greater apoptosis and 
subsequently increased cell death in breast cancer cells, as 
compared with the free-MTX and MTX-loaded un-crosslinked 
micelles. 
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It should be noted that free-MTX was less potent in inducing 
apoptosis as compared with the MTX-loaded nanocarriers. The 
low apoptosis inducing potency of free-MTX may have been a 
consequence of its low solubility in aqueous media. To 
investigate this phenomenon, a control experiment with MTX in 
DMSO was implemented, however, no apparent difference was 
found in induced apoptosis compared with MTX directly 
dissolved in cell culture media. These findings suggested that 
along with the low aqueous solubility, some other factors (e.g. 
low permeability and influx, higher efflux of MTX, and drug 
resistance etc.) could also be responsible for low cytotoxicity of 
free MTX.36, 37  Comparison with the formulated sodium salt of 
MTX was not carried out, as for a breast cancer indication, the 
conventional oral methotrexate sodium tablet formulation 
would not be suitable. 
To further confirm that cell death was induced via apoptosis 
(observed in the Hoechst/PI assays) by MTX-loaded 
formulations, annexin V-FITC/PI assays were performed. The 
findings of the annexin V-FITC/PI assay also revealed that MTX-
loaded core-crosslinked micelles induced apoptosis and finally 
death in tumour cells to a greater extent as compared with the 
MTX-loaded un-crosslinked micelles (Fig. 8) and free-MTX (Fig. 
S14). Therefore, the findings of annexin V-FITC/PI assays were 
in agreement with Hoechst/PI and MTT assays.  
In order to achieve better therapeutic effects, anticancer drugs 
must be internalized into the cancer cells at high 
concentrations. In terms of passive transmembrane diffusion, 
repulsive interactions between the negatively charged plasma 
membrane and MTX may cause difficulties in permeation of free 
MTX into the cell membrane, consequently decreasing 
therapeutic effectiveness. Furthermore, after being 
transported into the cytosol, higher cellular levels of MTX must 
be maintained, since the affinity of dihydrofolate reductase 
enzyme is greater to folate than MTX. However, maintaining 
high intracellular levels of MTX is difficult due to the limited 
influx and spontaneous efflux of free MTX.  
It is also worth noting that internalization of free MTX can occur 
via reduced-folate-carrier (RFC) mediated transport.56 The 
reduced-folate-carrier is an integral plasma membrane protein 
that mediates cellular transport of folates and antifolates (such 
as MTX). However, saturation of the reduced-folate-carrier at 
high MTX concentrations may occur which can inhibit the 
further uptake of the drug, therefore decreasing the 
therapeutic effectiveness.  In contrast, MTX-loaded micellar 
formulations are assumed to follow a different path of 
internalization such as passive endocytosis, avoiding the 
potential issues of receptor saturation. In addition, the 
approximately neutral charge of MTX-loaded un-crosslinked 
and crosslinked micelles may not have induced repulsive 
interactions at the negatively charged plasma membranes. 
Therefore, uptake of MTX-loaded micellar formulations by 
endocytic routes might have been more efficient than diffusion 
of free MTX alone, hence enhancing the influx of MTX within 
MCF7 cells as compared to the reduced-folate-carrier route of 
free MTX. The low cytotoxicity of free MTX may have also been 
a consequence of its reduced intracellular retention, which can 
occur by P-glycoprotein-mediated drug efflux in addition to the 
normal folate metabolism and excretion pathways. Since no 
intracellular efflux pumps are known for co-polymer micelles, 
and most characterised efflux pumps are at least partially 
membrane-associated, the cytotoxic activity of MTX-loaded 
micelles may also have been enhanced by the lack of any efflux 
mechanisms for the regions of the cell to which MTX was 
delivered by the in-situ reduced micelles. 
The findings of higher in vitro anti-cancer activity of MTX-loaded 
core-crosslinked micelles against MCF7 cells were consistent 
with the cellular uptake experiments. From internalization data, 
it could be deduced that MTX-loaded core-crosslinked micelles 
were more stable to dissociation both outside and inside the 
target cells. Thus the greater in vitro anti-cancer efficacy of 
MTX-loaded core-crosslinked micelles may have been due to 
the greater accumulation of MTX-loaded core-crosslinked 
micelles or release of MTX in cytoplasmic regions of MCF7 cells 
which were distant from efflux pump proteins. These data 
together suggest that further development of the redox-
responsive reversibly core-crosslinked micelles could be 
promising for tumour therapy and bioresponsive drug delivery 
applications. Experiments to evaluate the in vivo efficacy of 
these formulations are in progress. 
 
Conclusions 
In this study, functional micelles based on mPEG-b-poly(εCL-co-
αN3εCL) block copolymer were developed. An anticancer drug 
(methotrexate) was loaded into the hydrophobic cores of the 
micelles, which were further crosslinked by a redox responsive 
crosslinker to generate redox-responsive reversibly core-
crosslinked micelles. The redox-responsive core-crosslinked 
micelles released lower amounts of the drug under simplified 
(serum free) physiological conditions, however, rapid drug 
release was observed in reducing environments. Core-
crosslinked micelles were internalized by MCF7 cells 
quantitatively and mostly localized near the vicinity of cell 
nuclei. In contrast, un-crosslinked micelles were mostly 
localized in the cytoplasm of MCF7 cells. The cytotoxicity studies 
showed that empty un-crosslinked and core-crosslinked 
micelles were nontoxic to MCF7 cells. The MTX-loaded core-
crosslinked micelles inhibited the metabolic activity of MCF7 in 
a dose dependent manner, as compared to the MTX-loaded un-
crosslinked micelles and free MTX. The apoptosis assays 
revealed that MTX-loaded core-crosslinked micelles induced 
apoptosis and cell death in MCF7 cells to a greater extent as 
compared to the MTX-loaded un-crosslinked micelles and free 
MTX. Overall the data suggest that redox-responsive reversibly 
core-crosslinked micelles are promising candidates for disease-
activated drug delivery applications.  
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